Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
24 juin 2024 06h00 HE
|
Fractyl Health, Inc.
Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions
23 juin 2024 13h30 HE
|
Fractyl Health, Inc.
Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Platform at ADA 2024.
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
20 juin 2024 11h37 HE
|
Zealand Pharma
Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide ...
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
14 juin 2024 09h00 HE
|
Elevai Labs Inc.
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
12 juin 2024 08h30 HE
|
Wave Life Sciences USA, Inc.
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for...
NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk
12 juin 2024 07h00 HE
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib/IIa Trial in Obese Subjects with Cardiovascular Risk ...
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
07 juin 2024 04h30 HE
|
Boehringer Ingelheim
News builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic dysfunction-associated steatohepatitis (MASH)...
UMeWorld Announces June 4th webinar Registration Using New AI Investor Chatbot
30 mai 2024 08h00 HE
|
UMeWorld Limited
HONG KONG, May 30, 2024 (GLOBE NEWSWIRE) -- UMeWorld Limited (OTC:UMEWF), a leading company in ESG-based cooking oil and biofuel technologies, today announced the implementation of a cutting-edge AI...
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
29 mai 2024 07h00 HE
|
Fractyl Health, Inc.
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer
28 mai 2024 07h00 HE
|
NodThera
NodThera INC (“NodThera” or the “Company”) NodThera Announces Appointment of Daniel Swisher as Chief Executive Officer Dan joins NodThera with over 30 years of pharmaceutical industry leadership...